WallStreetZenWallStreetZen

NASDAQ: VIGL
Vigil Neuroscience Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VIGL

Based on 3 analysts offering 12 month price targets for Vigil Neuroscience Inc

Min Forecast
$13.00+660.23%
Avg Forecast
$16.33+855.15%
Max Forecast
$22.00+1,186.55%

Should I buy or sell VIGL stock?

Based on 3 analysts offering ratings for Vigil Neuroscience Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VIGL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VIGL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their VIGL stock forecasts and price targets.

VIGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-14
lockedlocked$00.00+00.00%2025-03-14
lockedlocked$00.00+00.00%2024-11-26

1 of 1

Forecast return on equity

Is VIGL forecast to generate an efficient return?

Company
5.21%
Industry
147.71%
Market
81.76%
VIGL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VIGL forecast to generate an efficient return on assets?

Company
3.17%
Industry
35.52%
VIGL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VIGL earnings per share forecast

What is VIGL's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.01
Avg 2 year Forecast
-$1.69
Avg 3 year Forecast
-$1.33

VIGL revenue forecast

What is VIGL's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$70.3M
Avg 2 year Forecast
$57.7M
Avg 3 year Forecast
$184.5M

VIGL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VIGL$1.71$16.33+855.15%Buy
AVTE$2.75N/AN/A
MGNX$1.26$2.00+58.73%Hold
EPIX$1.79$2.00+11.73%Hold
KYTX$1.86$16.00+760.22%Strong Buy
View Top Biotech Stocks

Vigil Neuroscience Stock Forecast FAQ

Is Vigil Neuroscience Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: VIGL) stock is to Buy VIGL stock.

Out of 3 analysts, 0 (0%) are recommending VIGL as a Strong Buy, 3 (100%) are recommending VIGL as a Buy, 0 (0%) are recommending VIGL as a Hold, 0 (0%) are recommending VIGL as a Sell, and 0 (0%) are recommending VIGL as a Strong Sell.

If you're new to stock investing, here's how to buy Vigil Neuroscience stock.

What is VIGL's earnings growth forecast for 2025-2027?

(NASDAQ: VIGL) Vigil Neuroscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Vigil Neuroscience's earnings in 2025 is -$84,256,000.On average, 5 Wall Street analysts forecast VIGL's earnings for 2025 to be -$93,623,097, with the lowest VIGL earnings forecast at -$107,811,244, and the highest VIGL earnings forecast at -$77,008,031. On average, 4 Wall Street analysts forecast VIGL's earnings for 2026 to be -$78,641,535, with the lowest VIGL earnings forecast at -$98,943,652, and the highest VIGL earnings forecast at -$41,070,950.

In 2027, VIGL is forecast to generate -$62,227,156 in earnings, with the lowest earnings forecast at -$107,811,244 and the highest earnings forecast at $0.

What is VIGL's revenue growth forecast for 2026-2028?

(NASDAQ: VIGL) Vigil Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Vigil Neuroscience's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VIGL's revenue for 2026 to be $3,278,675,264, with the lowest VIGL revenue forecast at $3,278,675,264, and the highest VIGL revenue forecast at $3,278,675,264. On average, 4 Wall Street analysts forecast VIGL's revenue for 2027 to be $2,693,180,869, with the lowest VIGL revenue forecast at $863,423,379, and the highest VIGL revenue forecast at $5,437,233,711.

In 2028, VIGL is forecast to generate $8,609,264,519 in revenue, with the lowest revenue forecast at $7,019,865,429 and the highest revenue forecast at $10,198,663,610.

What is VIGL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VIGL) forecast ROA is 3.17%, which is lower than the forecast US Biotechnology industry average of 35.52%.

What is VIGL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year VIGL price target, the average VIGL price target is $16.33, with the highest VIGL stock price forecast at $22.00 and the lowest VIGL stock price forecast at $13.00.

On average, Wall Street analysts predict that Vigil Neuroscience's share price could reach $16.33 by Mar 14, 2026. The average Vigil Neuroscience stock price prediction forecasts a potential upside of 855.15% from the current VIGL share price of $1.71.

What is VIGL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VIGL) Vigil Neuroscience's current Earnings Per Share (EPS) is -$2.07. On average, analysts forecast that VIGL's EPS will be -$2.01 for 2025, with the lowest EPS forecast at -$2.31, and the highest EPS forecast at -$1.65. On average, analysts forecast that VIGL's EPS will be -$1.69 for 2026, with the lowest EPS forecast at -$2.12, and the highest EPS forecast at -$0.88. In 2027, VIGL's EPS is forecast to hit -$1.33 (min: -$2.31, max: $0.00).

What is VIGL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VIGL) forecast ROE is 5.21%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.